LIFE : Summary for aTyr Pharma, Inc. - Yahoo Finance

U.S. Markets closed

aTyr Pharma, Inc. (LIFE)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.050.00 (0.00%)
At close: 4:00PM EDT
People also watch
QGENILMNPKIXRAYNWSA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.05
Open3.10
Bid0.00 x
Ask0.00 x
Day's Range3.05 - 3.16
52 Week Range2.10 - 4.45
Volume22,216
Avg. Volume144,311
Market Cap72.43M
BetaN/A
PE Ratio (TTM)-1.25
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire13 days ago

    aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors

    SAN DIEGO, April 10, 2017-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the ...

  • PR Newswire20 days ago

    aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors

    SAN DIEGO, April 3, 2017 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the appointment of Mr. Jeffrey S. Hatfield, as an independent board director, to aTyr Pharma's board of directors, effective immediately. Mr. Hatfield brings relevant industry operations experience and expertise to aTyr at an important and exciting time for aTyr's growth. Jeffrey S. Hatfield served as President, Chief Executive Officer of Vitae Pharmaceuticals from March 2004 through October 2016 when Vitae was acquired by Allergan, plc. During his tenure at Vitae, Mr. Hatfield focused the company on high value therapeutic areas with significant global unmet medical need, including autoimmune disorders, diabetes, immuno-oncology and more.

  • GlobeNewswire25 days ago

    aTyr Pharma to Present at Needham and Company 16th Annual Healthcare Conference

    SAN DIEGO, March 29, 2017-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the ...